KENNEWICK, Wash., Sept. 20, 2006 (PRIMEZONE) -- William J. Stokes has been appointed Chief Executive Officer of Advanced Medical Isotope Corporation (Pink Sheets:ADMD), a company engaged in the development of medical isotope products to be used in the diagnosis and treatment of cancer and other diseases.
Mr. Stokes has over 30 years experience in the business management, systems engineering, construction engineering, and maintenance of nuclear and conventional power generation facilities and safety-critical Department of Energy non-reactor nuclear facilities. As Founder and President of Columbia Basin Consulting Group, LLC, he has successfully managed daily operations and multiple federal business development initiatives with a variety of mission critical federal business development projects.
James C. Katzaroff, moving to the position of President, said "I am delighted to announce that we have found the right leader to guide Advanced Medical Isotope Corporation during this very exciting period while we begin to commercialize medical isotope technologies."
Bill Stokes states, "I am very enthusiastic for the future of ADMD. Our community has embraced the production and distribution of medical isotopes as the future of our economic diversification and provides an outstanding base of community support, economic development incentives, high quality nuclear professionals, and world premier nuclear research facilities. I am confident in our firm's ability to attract the seasoned professionals who are experienced and capable in executing a strong business plan in this exciting and growth business sector."
About Advanced Medical Isotope Corporation
Advanced Medical Isotope Corporation is engaged in the development of advanced production systems and processes for bringing previously unavailable medical isotopes to the marketplace and advancing systems for local product production. The field of nuclear medicine has routinely utilized radioisotopes in the diagnosis of disease while new processes are being pioneered for the targeted treatment of diseases such as cancer in preference to surgical techniques. Advanced Medical Isotope Corporation products support the accessibility to these less invasive therapeutic processes by advancing systems for lower cost production and improving supply availability of medical isotopes to hospitals and clinical treatment centers.
Forward-Looking Statements
Except for historical information contained herein, the matters set forth in this press release, such as statements relating to the company's ability to drive technological developments and the acceptance and timing of product introductions, are forward-looking statements that are subject to risks and uncertainties, including but not limited to, timely development and acceptance of new products, the impact of competitive products and pricing, the timely development and release of products by suppliers, and other risks.